G7163
α-半乳糖苷酶，位置特异性 来源于大肠杆菌
recombinant, expressed in E. coli, buffered aqueous solution
别名:
1,6-alpha-D-galactoside galactohydrolase, alpha-Galactosidase, melibiase
登录 查看组织和合同定价。
选择尺寸
关于此项目
化学文摘社编号:
UNSPSC Code:
12352204
NACRES:
NA.32
MDL number:
Specific activity:
≥20 units/mg protein
Recombinant:
expressed in E. coli
recombinant
expressed in E. coli
form
buffered aqueous solution
specific activity
≥20 units/mg protein
mol wt
80 kDa
shipped in
wet ice
storage temp.
2-8°C
Quality Level
Gene Information
Escherichia coli CFT073 ... melA(1037886)
Biochem/physiol Actions
从复杂的碳水化合物和糖蛋白中裂解 α（1→3）-和 α（1→6）-连接的非还原性末端半乳糖。在 pH 必须为中性或更高的条件下（例如，活细胞），这种方法对于去除 α-连接的半乳糖特别有效。
Physical form
该产品是无菌过滤的水性缓冲溶液。
Other Notes
在 pH 6.5，25°C 下，一个单位每分钟将水解 1 μ 摩尔对硝基苯基 α-D-吡喃半乳糖苷。
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
K Schmid et al.
European journal of biochemistry, 67(1), 95-104 (1976-08-01)
The utilization by Escherichia coli K12 of raffinose as sole carbon source depends on a new raffinose transport system, an invertase and an alpha-galactosidase specified by the Raf-plasmid D1021. The alpha-galactosidase was purified to homogeneity from a mutant strain with
Shuo Gao et al.
Frontiers in chemistry, 9, 709581-709581 (2021-08-03)
For wide applications of the lacZ gene in cellular/molecular biology, small animal investigations, and clinical assessments, the improvement of noninvasive imaging approaches to precisely assay gene expression has garnered much attention. In this study, we investigate a novel molecular platform
Camilla Tøndel et al.
Journal of the American Society of Nephrology : JASN, 24(1), 137-148 (2013-01-01)
The effect of early-onset enzyme replacement therapy on renal morphologic features in Fabry disease is largely unknown. Here, we evaluated the effect of 5 years of treatment with agalsidase alfa or agalsidase beta in 12 consecutive patients age 7-33 years
Antonio Pisani et al.
Molecular genetics and metabolism, 107(3), 267-275 (2012-09-12)
Anderson-Fabry disease is an X-linked lysosomal storage disorder resulting from the deficiency of the hydrolytic enzyme alpha galactosidase A, with consequent accumulation of globotrioasoyl ceramide in cells and tissues of the body, resulting in a multi-system pathology including end organ
Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.
Aritz Pérez Ruiz de Garibay et al.
Drug design, development and therapy, 6, 303-310 (2012-11-03)
Gene-mediated enzyme replacement is a reasonable and highly promising approach for the treatment of Fabry disease (FD). The objective of the present study was to demonstrate the potential applications of solid lipid nanoparticle (SLN)-based nonviral vectors for the treatment of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持